Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.73USD
19 Feb 2019
Change (% chg)

$-0.04 (-1.44%)
Prev Close
$2.77
Open
$2.78
Day's High
$2.79
Day's Low
$2.65
Volume
120,107
Avg. Vol
346,394
52-wk High
$4.04
52-wk Low
$1.85

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $234.22
Shares Outstanding(Mil.): 84.55
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -0.20 -- --
ROI: -42.00 8.92 14.45
ROE: -42.26 10.08 15.96

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

11 Feb 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK, Feb 11 Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

11 Feb 2019

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

UPDATE 1-U.S. FDA approves Catalyst Pharma's rare disease drug

Nov 28 The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

U.S. FDA approves Catalyst Pharma's rare disease drug

Nov 28 The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

Earnings vs. Estimates